HPS1 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q92902 |
---|---|
Other Accession | NP_872577.1, NP_000186.2 |
Clone Names | 90723189 |
Gene ID | 3257 |
---|---|
Other Names | Hermansky-Pudlak syndrome 1 protein, HPS1, HPS |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | HPS1 |
---|---|
Synonyms | HPS |
Function | Component of the BLOC-3 complex, a complex that acts as a guanine exchange factor (GEF) for RAB32 and RAB38, promotes the exchange of GDP to GTP, converting them from an inactive GDP-bound form into an active GTP-bound form. The BLOC-3 complex plays an important role in the control of melanin production and melanosome biogenesis and promotes the membrane localization of RAB32 and RAB38 (PubMed:23084991). |
Tissue Location | Ubiquitous. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a protein that may play a role inorganelle biogenesis associated with melanosomes, platelet densegranules, and lysosomes. The encoded protein is a component ofthree different protein complexes termed biogenesis oflysosome-related organelles complex (BLOC)-3, BLOC4, and BLOC5.Mutations in this gene are associated with Hermansky-Pudlaksyndrome type 1. Multiple transcript variants encoding distinctisoforms have been identified for this gene; the full-lengthsequences of some of these have not been determined yet. [providedby RefSeq].
References
Sandrock, K., et al. Klin Padiatr 222(3):168-174(2010)Kloer, D.P., et al. J. Biol. Chem. 285(10):7794-7804(2010)Wei, A., et al. J. Invest. Dermatol. 130(3):716-724(2010)Wei, A., et al. J. Dermatol. Sci. 56(2):130-132(2009)Fernandez, L.P., et al. Exp. Dermatol. 18(7):634-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.